2024-09-18 - Analysis Report
## JNJ Stock Analysis Report

**Company Overview:** Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer goods company. 

**Performance Summary:**

**1. Relative Performance:**
   * **Cumulative Return:** JNJ: 20.41%, S&P 500 (VOO): 88.56%
   * **Underperformance:** JNJ has significantly underperformed the S&P 500, lagging behind by 68.15% in cumulative returns. 
   * **Relative Divergence:**  The current relative divergence is at the 14.65% percentile, indicating that JNJ's performance against the S&P 500 is currently in the bottom 15% of its historical range. 

**2. Recent Price Action:**
   * **Closing Price:** $166.74
   * **5-Day Moving Average:** $165.74
   * **20-Day Moving Average:** $164.81
   * **60-Day Moving Average:** $157.75

**3. Technical Indicators:**
   * **RSI:** 62.05 (Slightly overbought)
   * **PPO:** -0.13 (Bearish signal)
   * **Delta_Previous_Relative_Divergence:** -5.1 (Short-term bearish momentum)
   * **Expected Return:** 11.72% (Potential 5-year maximum return)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | $22.45B | 
| 2024-05-01 | 1.35 | $21.38B | 
| 2024-02-16 | 1.68 | $21.39B | 
| 2023-10-27 | 10.32 | $21.35B | 
| 2024-02-16 | 10.32 | $21.35B | 

* **Recent Earnings (2024-07-25):** EPS of $1.95 slightly exceeded analyst expectations.
* **Outlook:** JNJ's revenue and earnings growth have been relatively stable, and the company continues to invest in research and development.  However, continued challenges in the pharmaceutical industry, including pricing pressures and increased competition, could impact future growth.

**Overall Analysis:**

JNJ has significantly underperformed the broader market in recent years, lagging behind the S&P 500 by a significant margin. While the company's recent earnings beat expectations, technical indicators suggest some short-term bearish momentum, and its relative performance against the S&P 500 remains weak. Despite the company's strong fundamentals and long-term growth potential, investors should be aware of the challenges facing the pharmaceutical industry and exercise caution before investing in JNJ.  

**Recommendation:** 

Based on the current analysis, JNJ may be a potential investment opportunity for long-term investors seeking a diversified portfolio with exposure to the healthcare sector. However, investors should exercise caution due to the company's recent underperformance and consider diversifying their investment portfolio. 
